BioScrip to Present at Bank of America Merrill Lynch 2017 Leveraged Finance Conference
November 16 2017 - 9:00AM
BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the
largest independent national provider of infusion and home care
management solutions, today announced that Daniel E. Greenleaf,
President and Chief Executive Officer, and Stephen Deitsch, Senior
Vice President, Chief Financial Officer and Treasurer, will present
at the Bank of America Merrill Lynch 2017 Leveraged Finance
Conference on Wednesday, November 29, 2017, at 8:10 a.m. EST.
The conference will be held at the Boca Raton Resort &
Club in Boca Raton, FL.
A live webcast of the presentation and copies of the materials
presented can be accessed via BioScrip’s Investor Relations website
at
https://investors.bioscrip.com/events-and-presentations/upcoming-events
or through the following
link:http://www.veracast.com/webcasts/baml/levfin2017/id22103128559.cfm.
About BioScrip, Inc.
BioScrip, Inc. is the largest independent national provider of
infusion and home care management solutions, with approximately
2,200 teammates and nearly 80 service locations across the U.S.
BioScrip partners with physicians, hospital systems, payors,
pharmaceutical manufacturers and skilled nursing facilities to
provide patients access to post-acute care services. BioScrip
operates with a commitment to bring customer-focused pharmacy and
related healthcare infusion therapy services into the home or
alternate-site setting. By collaborating with the full spectrum of
healthcare professionals and the patient, BioScrip provides
cost-effective care that is driven by clinical excellence, customer
service, and values that promote positive outcomes and an enhanced
quality of life for those it serves.
Investor Contacts:
Stephen Deitsch
Chief Financial Officer
& Treasurer
T: (720) 697-5200
stephen.deitsch@bioscrip.com
David ClairICR, Inc.T: (646)
277-1266david.clair@icrinc.com
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024